Risk assessment and strategies to achieve lipid goals: lessons from real-world clinical practice

Area of Science:

• Cardiology
• Clinical Practice
• Lipid Metabolism

Background:

• Dyslipidemia management is critical for preventing coronary heart disease (CHD).
• Accurate risk stratification guides treatment intensity and lipid goal achievement.
• Clinical case studies highlight challenges in risk assessment for specific patient groups.

Observation:

• Peripheral arterial disease (PAD) patients face high CHD and cardiovascular mortality risk, necessitating aggressive lipid management.
• Population-based risk algorithms may underestimate CHD risk in heterozygous familial hypercholesterolemia (hFH).

Findings:

• Patients with PAD require intensive lipid-lowering therapy regardless of initial cholesterol levels.
• hFH patients are at elevated CHD risk and benefit from aggressive lipid-modifying treatments.

Implications:

• Tailored CHD risk assessment is vital for effective dyslipidemia treatment.
• Consideration of specific conditions like PAD and hFH is essential for personalized care.
• Family screening in hFH can identify additional high-risk individuals for early intervention.